Skip to main content

Notification of Change

In order to improve the service to our users we have made some changes to our repertoire Validation/verification of these assays has been performed.

Changes include:

  • Urine drug screen on the Thermo Orbitrap accurate Mass Spectrometry
  • Neuroleptic drug panel (Clozapine, Olanzepine, Rispiridone, Quetiapine) on the TQ-S micro
  • AED Drug panel (Levetiracetamin, Lamotrigine, Topiramate, Oxcarbazepine) on the TQ-s micro
  • Total Homocysteine TQS LC MS/MS
  • Testosterone on the ABSciex 5500
  • 17OHP on the Sciex 6500+Qtrap
  • 5HIAA on the ABSciex 5500
  • Dexamethasone on the Sciex 6500+Qtrap
  • IgG subclassess on the Optilite analyser
  • Methotrexate on the Alinity analyser
  • Vancomycin on the Alinity analyser
  • Tobramycin on the Alinity analyser
  • Amiakacin on the Alinity analyser

However some of these assays now lie outside our scope of accreditation as assessed by UKAS. UKAS have been informed and will assess these changes as an extension to scope of our accreditation in January 2022. This is normal procedure when changing analyser platforms/methodology